Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PDK1 | Q15118 | 5/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304803 | 1.00 | USP2 (0.53) | USP2SMN1; SMN2PDK1NR1H2RECQL | |
| SCHEMBL8904969 | 1.00 | USP2 (0.53) | USP2SMN1; SMN2PDK1NR1H2RECQL | |
| SCHEMBL553919 | 1.00 | USP2 (0.53) | USP2SMN1; SMN2PDK1NR1H2RECQL | |
| SCHEMBL306580 | 0.91 | PDK1 (0.52) | USP2SMN1; SMN2PDK1NR1H2RECQL | |
| SCHEMBL305277 | 0.91 | PDK1 (0.52) | USP2SMN1; SMN2PDK1NR1H2RECQL | |
| SCHEMBL305278 | 0.91 | PDK1 (0.52) | USP2SMN1; SMN2PDK1NR1H2RECQL | |
| SCHEMBL29864929 | 0.91 | RECQL (0.49) | USP2SMN1; SMN2PDK1NR1H2RECQL | |
| SCHEMBL30987096 | 0.90 | HPGD (0.49) | USP2SMN1; SMN2PDK1NR1H2RECQL | |
| SCHEMBL1655537 | 0.88 | USP2 (0.50) | USP2SMN1; SMN2PDK1NR1H2RECQL | |
| SCHEMBL31040994 | 0.88 | USP2 (0.50) | USP2SMN1; SMN2PDK1NR1H2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 866 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117777048-B | Preparation method of chiral 2-hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester | 上海科利生物医药有限公司 | 2024-09-20 | — | — | CN | claimed |
| CN-117777048-A | Preparation method of chiral 2-hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester | 上海科利生物医药有限公司 | 2024-03-29 | — | — | CN | claimed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4743465-A1 | BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-12624043-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4735114-A1 | SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES | Masarykova Univerzita (CZ) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026087613-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS, PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731216-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2026-04-29 | — | — | EP | disclosed |
| US-12606561-B2 | Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2026-04-21 | — | — | US | disclosed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| CN-1107151-A | Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders | SANKYO CO (JP) | 1995-08-23 | — | — | CN | disclosed |
| CN-1028527-C | Process for preparing coumarin derivatives | SANKYO CO (JP) | 1995-05-24 | — | — | CN | disclosed |
| EP-0411912-B1 | Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders | SANKYO CO (JP) | 1995-04-19 | — | — | EP | disclosed |
| US-5393760-A | Cardiovascular disorders, antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0468231-B1 | Guanidins | HOFFMANN LA ROCHE (CH) | 1994-09-21 | — | — | EP | disclosed |
| US-5260307-A | Inhibit thrombin-induced platlet aggregation and clotting of fibrogen in plasma | HOFMANN-LA ROCHE INC. (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0468231-A2 | Guanidins | F. HOFFMANN-LA ROCHE AG (CH) | 1992-01-29 | — | — | EP | disclosed |
| CN-1049662-A | Coumarin derivative, preparation thereof and application thereof in treating cerebrovascular disorder | SANKYO CO (JP) | 1991-03-06 | — | — | CN | disclosed |
| EP-0411912-A2 | Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders | Sankyo Company Limited (JP) | 1991-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606561-B2 | Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | CDK6, CDKL1, CDK3 | USP2 2191/4885SMN1; SMN2 4257/4885PDK1 341/4885 |
| US-12624043-B2 | Compositions useful for treating disorders related to kit | KIT, RET, SLC26A4 | USP2 2177/4885SMN1; SMN2 549/4885PDK1 1725/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | USP2 3246/4885SMN1; SMN2 1780/4885PDK1 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.